{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:18:55Z","timestamp":1791119935292,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Qihang Project of Fujian Medical University","award":["2020QH1282"],"award-info":[{"award-number":["2020QH1282"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10157-024-02501-x","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T01:01:52Z","timestamp":1712970112000},"page":"902-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study"],"prefix":"10.1007","volume":"28","author":[{"given":"Xiaolu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongpu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"2501_CR1","first-page":"e34332","volume":"15","author":"GG Alahmadi","year":"2023","unstructured":"Alahmadi GG, El-Desoky SM, Al Zahrani RA, Kari JA. Lupus nephritis in an adolescent girl with hyper-immunoglobulin E. Cureus. 2023;15:e34332.","journal-title":"Cureus"},{"key":"2501_CR2","doi-asserted-by":"publisher","first-page":"112799","DOI":"10.1016\/j.biopha.2022.112799","volume":"149","author":"YJ Wang","year":"2022","unstructured":"Wang YJ, Li YX, Li S, et al. Progress in traditional Chinese medicine and natural extracts for the treatment of lupus nephritis. Biomed Pharmacother. 2022;149:112799.","journal-title":"Biomed Pharmacother"},{"key":"2501_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clim.2016.11.019","volume":"185","author":"C Arriens","year":"2017","unstructured":"Arriens C, Chen S, Karp DR, et al. Prognostic significance of repeat biopsy in lupus nephritis: histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017;185:3\u20139.","journal-title":"Clin Immunol"},{"key":"2501_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12:825\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2501_CR5","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.jaut.2022.102871","volume":"132","author":"C Yu","year":"2022","unstructured":"Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022;132:102871.","journal-title":"J Autoimmun"},{"key":"2501_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","volume":"76","author":"SV Parikh","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76:265\u201381.","journal-title":"Am J Kidney Dis"},{"key":"2501_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clim.2018.08.013","volume":"206","author":"C Adamichou","year":"2019","unstructured":"Adamichou C, Georgakis S, Bertsias G. Cytokine targets in lupus nephritis: current and future prospects. Clin Immunol. 2019;206:42\u201352.","journal-title":"Clin Immunol"},{"key":"2501_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"DS Telitacicept","year":"2021","unstructured":"Telitacicept DS. First approval. Drugs. 2021;81:1671\u20135.","journal-title":"Drugs"},{"key":"2501_CR9","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/cns.13904","volume":"28","author":"J Ding","year":"2022","unstructured":"Ding J, Jiang X, Cai Y, Pan S, Deng Y, Gao M. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study. CNS Neurosci Ther. 2022;28:1613\u201323.","journal-title":"CNS Neurosci Ther"},{"key":"2501_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. 2023;32:94\u2013100.","journal-title":"Lupus"},{"key":"2501_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14752","author":"JW Chen","year":"2023","unstructured":"Chen JW, Zhan JY, Liang SP. A patient with refractory proliferative lupus nephritis treated with telitacicept: a case report. Int J Rheum Dis. 2023. https:\/\/doi.org\/10.1111\/1756-185X.14752.","journal-title":"Int J Rheum Dis"},{"key":"2501_CR12","first-page":"1656","volume":"32","author":"RN Alvarado","year":"2023","unstructured":"Alvarado RN, Alle G, Tobar-Jaramillo MA, et al. Burden of lupus activity on health care resources utilization in Buenos Aires. Argentina. 2023;32:1656\u201365.","journal-title":"Argentina"},{"key":"2501_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","volume":"58","author":"Y Fan","year":"2022","unstructured":"Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc). 2022;58:23\u201332.","journal-title":"Drugs Today (Barc)"},{"key":"2501_CR14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43:666\u201373.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2501_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","volume":"31","author":"L Sun","year":"2022","unstructured":"Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus. 2022;31:998\u20131006.","journal-title":"Lupus"},{"key":"2501_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35:630\u201340.","journal-title":"Arthritis Rheum"},{"key":"2501_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/1756-185X.14613","volume":"26","author":"X Guan","year":"2023","unstructured":"Guan X, Zhao Z. Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus. Int J Rheum Dis. 2023;26:1399\u2013402.","journal-title":"Int J Rheum Dis"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02501-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:35:57Z","timestamp":1724409357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02501-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2501"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02501-x","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}